drugset

drugset / Trial / NCT00704418

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

NCT00704418 ↗

Phase 3 Completed 156 enrolled Bausch & Lomb Incorporated

RandomizedParallel-groupDouble-blindTreatment

Summary

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Timeline

Start: 2008-06
Primary completion: 2009-01
Completion: 2009-12

Outcome

Met primary endpoint

paper The bromfenac 0.09% group was significantly higher compared to the placebo group PMID 21751945 ↗

paper the primary endpoint of the proportion of subjects who had cleared ocular inflammation by Day 15 (P < 0.0001). PMID 21751945 ↗

Publications

Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR; Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011 Sep;27(9):1693-703. doi: 10.1185/03007995.2011.597663. Epub 2011 Jul 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bromfenac	Other / unclassified	0.09 %	—

Indications